Impact of 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya
Authors:
- Laura L. HammittLHLaura L. Hammitt
- Anthony O. EtyangAEAnthony O. Etyang
- Susan C. MorpethSMSusan C. Morpeth
- John OjalJOJohn Ojal
- Alex MutukuAMAlex Mutuku
- Neema MturiNMNeema Mturi
- Jennifer C. MoisiJMJennifer C. Moisi
- Ifedayo M. AdetifaIAIfedayo M. Adetifa
- Angela KaraniAKAngela Karani
- Donald O. AkechDADonald O. Akech
- Mark OtiendeMOMark Otiende
- Tahreni BwanaaliTBTahreni Bwanaali
Preprint
Abstract
Background: 10-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10 and 14 weeks of age, was introduced in Kenya in January 2011, accompanied by a catch-up campaign in Kilifi County for children <5 years. Coverage with ≥2 PCV10 doses in children 2-11 months was 80% in 2011 and 84% in 2016; coverage with ≥1 dose in children 12-59 months was 66% and 87%, respectively. Methods: Clinical and microbiological surveillance for invasive pneumococcal disease (IPD) among admissions of all ages at Kilifi County Hospital was linked to the Kilifi Health and Demographic Surveillance System from 1999-2016. We calculated the incidence rate ratio (IRR) comparing the pre-vaccine and post-vaccine eras, adjusted for confounding, and reported percent reduction in IPD as 1-IRR. Annual cross-sectional surveys of nasopharyngeal carriage were conducted from 2009-2016. Findings: Surveillance identified 667 IPD cases in 3,211,403 person-years of observation. IPD incidence in children <5 years fell sharply in 2011 following PCV10 introduction, and remained low (PCV10-type IPD: 60·8 vs 3·2/100,000 [92% reduction; 95%CI: 78, 97]; overall IPD: 81·6 vs 15·3/100,000 [68% reduction; 95%CI: 40, 83]; 1999-2010 vs 2012-2016). PCV10-type IPD also declined significantly in unvaccinated age groups (<2 months, 5-14 years, ≥15 years), with estimated reductions of 100%, 74%, and 81%, respectively. There was no significant change in the incidence of non-PCV10 type IPD. In children aged <5 years, PCV10-type carriage declined by 74% and non-PCV10-type carriage increased by 71%. Interpretation: Introduction of PCV10 in Kenya resulted in a substantial reduction in PCV10-type IPD in children and adults without significant replacement disease. These findings suggest that routine infant PCV10 immunization programmes with catch-up campaigns will provide substantial direct and indirect protection in low-income settings in tropical Africa.Keywords
This publication has 29 references indexed in Scilit:
- Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literatureVaccine, 2017
- Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studiesThe Lancet Global Health, 2014
- Burden of disease in adults admitted to hospital in a rural region of coastal Kenya: an analysis of data from linked clinical and demographic surveillance systemsThe Lancet Global Health, 2014
- Profile: The Kilifi Health and Demographic Surveillance System (KHDSS)International Journal of Epidemiology, 2012
- Effectiveness of Haemophilus influenzae Type b Conjugate Vaccine Introduction Into Routine Childhood Immunization in KenyaJAMA, 2006
- Sequential Multiplex PCR Approach for Determining Capsular Serotypes of Streptococcus pneumoniae IsolatesJournal of Clinical Microbiology, 2006
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- Bacteremia among Children Admitted to a Rural Hospital in KenyaNew England Journal of Medicine, 2005
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- Diagnosis of acute bacterial meningitis in children at a district hospital in sub-Saharan AfricaThe Lancet, 2001